Investors might want to bet on Stoke Therapeutics, Inc. (STOK) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the sys ...

Stoke Therapeutics, Inc. (STOK) shares ended the last trading session 12% higher at $8.61. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 5.6% loss over the past four weeks.The sudden price rise can be attributed to growing investors' optimism related to the company’s progress with the development of its pipeline candidate zorevunersen for treating Dravet syndrome.This company is expected to post quarterly loss of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38938 Stoke Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorporation o ...

Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.60 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 64.71%. A quarter ago, it was expected that this company would post a loss of $0.52 per share when it actually produced a loss of $0.47, delivering a surprise of 9.62%.Over the last four quarters, the company has ...

Financial Performance - The net loss for the year ended December 31, 2024 was $89.0 million, or $1.65 per share, compared to a net loss of $104.7 million, or $2.38 per share for 2023[7]. - The company reported a net loss of $10.5 million, or $0.18 per share, for the fourth quarter of 2024, compared to a net loss of $27.0 million, or $0.60 per share, for the same period in 2023[7]. - The net loss for the three months ended December 31, 2024, was $10,483 million, a decrease from a net loss of $26,958 million in the same period of 2023, indicating improved financial performance[17]. - Comprehensive loss for the year ended December 31, 2024, was $89,108 million, a decrease from $103,548 million in 2023, indicating a reduction in overall losses[17]. Revenue and Income - Revenue recognized from the License and Collaboration Agreement with Acadia Pharmaceuticals for the year ended December 31, 2024 was $36.6 million, a significant increase from $8.8 million in 2023[7]. - Revenue for the three months ended December 31, 2024, was $22,614 million, compared to $2,801 million for the same period in 2023, representing a significant increase[17]. - Total other income for the three months ended December 31, 2024, was $3,171 million, compared to $2,629 million in 2023, showing an increase of 20.7%[17]. Expenses - Research and development expenses for the year ended December 31, 2024 were $89.1 million, up from $82.2 million in 2023[7]. - General and administrative expenses for the year ended December 31, 2024 were $48.8 million, compared to $41.3 million in 2023[7]. - Total operating expenses for the three months ended December 31, 2024, were $36,268 million, up from $32,388 million in 2023, reflecting a year-over-year increase of 5.4%[17]. - Research and development expenses for the year ended December 31, 2024, totaled $89,133 million, an increase from $82,231 million in 2023, highlighting ongoing investment in innovation[17]. - General and administrative expenses for the year ended December 31, 2024, were $48,794 million, compared to $41,322 million in 2023, reflecting a year-over-year increase of 18.1%[17]. Cash and Funding - As of December 31, 2024, the company had $246.7 million in cash, cash equivalents, and marketable securities, which, along with the $165 million upfront payment from the Biogen collaboration, is expected to fund operations to mid-2028[1][7]. - The company is well-capitalized to advance through Phase 3 and prepare for launch readiness of zorevunersen[2]. Research and Development - The company plans to initiate the Phase 3 EMPEROR study of zorevunersen in the second quarter of 2025, following successful alignment with regulatory agencies[2][3]. - The FDA granted Breakthrough Therapy Designation for zorevunersen for the treatment of Dravet syndrome with a confirmed mutation in the SCN1A gene[4]. - The company retains exclusive rights for zorevunersen in the United States, Canada, and Mexico, while Biogen has exclusive commercialization rights for the rest of the world[3]. Share Information - The weighted average common shares outstanding for the three months ended December 31, 2024, increased to 57,029,296 from 44,958,894 in 2023, indicating a rise in share issuance[17]. Marketable Securities - The company reported an unrealized loss on marketable securities of $(317) million for the three months ended December 31, 2024, compared to a gain of $122 million in the same period of 2023[17].

Stoke Therapeutics, Inc. (STOK) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they ...

Stoke Therapeutics (NASDAQ: NASDAQ: STOK ) develops RNA-based treatments for severe neurological and ophthalmic disorders. Although the stock is volatile, its unique strategy for restoring protein expression in haploinsufficient diseases makes it a possible long-term winner. Its lead candidate, zorevunersen, is nearingI have a strong inclination towards high-growth companies, often treading in sectors poised for exponential expansion. My expertise lies in understanding and investing in disruptive technologi ...

Stoke Therapeutics, Inc. (STOK) shares soared 9.4% in the last trading session to close at $12.60. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 4.5% gain over the past four weeks.Last month, the company achieved alignment with various regulatory agencies across the world related to the design of the phase III EMPEROR study on its pipeline candidate, zorevunersen, for treating Dravet syndrome. Following discussions with the FDA ...

Massachusett-based Stoke Therapeutics (STOK) is making rapid progress with the development of zorevunersen (STK-001), its investigational candidate for treating Dravet syndrome, a severe and progressive genetic epilepsy.Zorevunersen is a novel proprietary antisense oligonucleotide with the potential to become the first disease-modifying therapy to address the genetic cause of Dravet syndrome.The FDA granted a Breakthrough Therapy designation to zorevunersen for treating Dravet syndrome in December 2024.In t ...

Group 1 - The stock price of Stoke Therapeutics, Inc. (STOK) has recently experienced a bearish trend, losing 14.8% over the past week, but a hammer chart pattern suggests a potential trend reversal as buying interest may be increasing [1] - The hammer chart pattern indicates a possible bottom formation, signaling that selling pressure may be exhausting, which could lead to a reversal in the stock's price trend [2] - There has been a positive trend in earnings estimate revisions for STOK, with a 3.3% increase in the consensus EPS estimate for the current year over the last 30 days, indicating bullish sentiment among analysts [3] Group 2 - STOK holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [3] - The Zacks Rank serves as a timing indicator, suggesting that the company's prospects are improving, further supporting the potential for a turnaround in STOK's stock price [3]